+1 (888) 794-0077
X
X
Contact Us
Solutions
IND-Enabling
NDA-Enabling
Small Molecule
Large Molecule
New Modalities
Oligonucleotide Solutions
Antibody-Drug Conjugates
Peptides
Protein Degrader Solutions
CAR-T
mRNA
Talk to an Expert
Testing Services
Bioanalysis
Small Molecule Bioanalysis
Large Molecule Bioanalysis
Discovery
Preclinical
Clinical
Biomarkers
Bioanalytical Methods
Central Lab Services
DMPK
In Vitro ADME
Metabolic Stability
Drug-Drug Interaction
Kinetic & Thermodynamic Solubility
Plasma Protein Binding
Rodent PK
Large Animal PK
Non-GLP Bioanalysis
Metabolite Profiling & ID
Non-Clinical Mass Balance & Tissue Distribution
Human Radiolabel-AME
Radiolabeled In Vivo PK/ADME Studies
Safety Assessment
General Toxicology
Safety Pharmacology
Genetic Toxicology
In Vitro Toxicology
Developmental & Reproductive Toxicology
Carcinogenicity Testing Services
Ophthalmology
Preclinical Development of Biologics
Preclinical Immunology
Vaccine Development
Standard for Exchange of Nonclinical Data (SEND)
Preclinical Pathology
Repeat Dose Toxicity
Dose Ranging & MTD Studies
Single Dose Acute Toxicity Testing
Molecular Imaging Services
Company
WuXi AppTec Lab Testing Leadership Team
Global Facilities & Compliance
Contact Us
Insights
Blog
Digital Learning
Trade Articles
Events
Meet Our Experts
Select Page
Jianbo Diao
Categories
COVID-19
Preclinical Safety
Preclinical Testing
Regulatory
Regulatory Expertise
Technical Expertise
Recent Posts
GLP vs. Non-GLP Tox: Choosing the Right Study Design
What Are GLP Toxicology Studies and Why Are They Required?
Five Ways to Accelerate Peptide and Oligonucleotide Development Through Integrated Toxicology Studies
Toxicology Studies in Drug Development: What Programs Often Underestimate
Acute Toxicity Studies: Best Practices for First-In-Human Readiness
